Role of adjuvant therapy in intermediate-risk cervical cancer
patients - Subanalyses of the SCCAN study

J 2023

Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study

CIBULA, David, Huseyin AKILLI, Jiří JARKOVSKÝ, Luc VAN LONKHUIJZEN, Giovanni SCAMBIA et. al.

Základní údaje

Originální název

Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study

Autoři

CIBULA, David (203 Česká republika, garant), Huseyin AKILLI, Jiří JARKOVSKÝ (203 Česká republika, domácí), Luc VAN LONKHUIJZEN, Giovanni SCAMBIA, Mehmet Mutlu MEYDANLI, David Isla ORTIZ, Henrik FALCONER, Nadeem R ABU-RUSTUM, Diego ODETTO, Jaroslav KLAT (203 Česká republika), dos Reis RICARDO, Ignacio ZAPARDIEL, Di Martino GIAMPAOLO, Jiri PRESL (203 Česká republika), Rene LAKY, Aldo LOPEZ, Vít WEINBERGER (203 Česká republika, domácí), Andreas OBERMAIR, Rene PAREJA, Renata PONCOVA (203 Česká republika), Constantijne MOM, Nicolo BIZZARRI, Martina BORCINOVA (203 Česká republika), Koray ASLAN, Rosa Angelica Salcedo HERNANDEZ, Guus FONS, Klára BENEŠOVÁ (203 Česká republika, domácí), Lukas DOSTALEK (203 Česká republika) a Ali AYHAN

Vydání

Gynecologic oncology, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023, 0090-8258

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.700 v roce 2022

Kód RIV

RIV/00216224:14110/23:00131019

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ygyno.2023.01.014

UT WoS

000940806800001

Klíčová slova anglicky

Cervical cancer; Intermediate risk; GOG criteria; Radial surgery; Adjuvant treatment; Radiotherapy

Štítky

14110240, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 6. 2023 08:45, Mgr. Tereza Miškechová

Anotace

V originále

Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy. (c) 2023 Elsevier Inc. All rights reserved.

Citovat

CIBULA, David, Huseyin AKILLI, Jiří JARKOVSKÝ, Luc VAN LONKHUIJZEN, Giovanni SCAMBIA, Mehmet Mutlu MEYDANLI, David Isla ORTIZ, Henrik FALCONER, Nadeem R ABU-RUSTUM, Diego ODETTO, Jaroslav KLAT, dos Reis RICARDO, Ignacio ZAPARDIEL, Di Martino GIAMPAOLO, Jiri PRESL, Rene LAKY, Aldo LOPEZ, Vít WEINBERGER, Andreas OBERMAIR, Rene PAREJA, Renata PONCOVA, Constantijne MOM, Nicolo BIZZARRI, Martina BORCINOVA, Koray ASLAN, Rosa Angelica Salcedo HERNANDEZ, Guus FONS, Klára BENEŠOVÁ, Lukas DOSTALEK a Ali AYHAN. Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study. Gynecologic oncology. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023, roč. 170, March 2023, s. 195-202. ISSN 0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2023.01.014.

@article{2292977,
   author = {Cibula, David and Akilli, Huseyin and Jarkovský, Jiří and van Lonkhuijzen, Luc and Scambia, Giovanni and Meydanli, Mehmet Mutlu and Ortiz, David Isla and Falconer, Henrik and AbuandRustum, Nadeem R and Odetto, Diego and Klat, Jaroslav and Ricardo, dos Reis and Zapardiel, Ignacio and Giampaolo, Di Martino and Presl, Jiri and Laky, Rene and Lopez, Aldo and Weinberger, Vít and Obermair, Andreas and Pareja, Rene and Poncova, Renata and Mom, Constantijne and Bizzarri, Nicolo and Borcinova, Martina and Aslan, Koray and Hernandez, Rosa Angelica Salcedo and Fons, Guus and Benešová, Klára and Dostalek, Lukas and Ayhan, Ali},
   article_location = {SAN DIEGO},
   article_number = {March 2023},
   doi = {http://dx.doi.org/10.1016/j.ygyno.2023.01.014},
   keywords = {Cervical cancer; Intermediate risk; GOG criteria; Radial surgery; Adjuvant treatment; Radiotherapy},
   language = {eng},
   issn = {0090-8258},
   journal = {Gynecologic oncology},
   title = {Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study},
   url = {https://www.sciencedirect.com/science/article/pii/S0090825823000148?via%3Dihub},
   volume = {170},
   year = {2023}
}

TY  - JOUR
ID  - 2292977
AU  - Cibula, David - Akilli, Huseyin - Jarkovský, Jiří - van Lonkhuijzen, Luc - Scambia, Giovanni - Meydanli, Mehmet Mutlu - Ortiz, David Isla - Falconer, Henrik - Abu-Rustum, Nadeem R - Odetto, Diego - Klat, Jaroslav - Ricardo, dos Reis - Zapardiel, Ignacio - Giampaolo, Di Martino - Presl, Jiri - Laky, Rene - Lopez, Aldo - Weinberger, Vít - Obermair, Andreas - Pareja, Rene - Poncova, Renata - Mom, Constantijne - Bizzarri, Nicolo - Borcinova, Martina - Aslan, Koray - Hernandez, Rosa Angelica Salcedo - Fons, Guus - Benešová, Klára - Dostalek, Lukas - Ayhan, Ali
PY  - 2023
TI  - Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
JF  - Gynecologic oncology
VL  - 170
IS  - March 2023
SP  - 195-202
EP  - 195-202
PB  - ACADEMIC PRESS INC ELSEVIER SCIENCE
SN  - 00908258
KW  - Cervical cancer
KW  - Intermediate risk
KW  - GOG criteria
KW  - Radial surgery
KW  - Adjuvant treatment
KW  - Radiotherapy
UR  - https://www.sciencedirect.com/science/article/pii/S0090825823000148?via%3Dihub
N2  - Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy. (c) 2023 Elsevier Inc. All rights reserved.
ER  -

CIBULA, David, Huseyin AKILLI, Jiří JARKOVSKÝ, Luc VAN LONKHUIJZEN, Giovanni SCAMBIA, Mehmet Mutlu MEYDANLI, David Isla ORTIZ, Henrik FALCONER, Nadeem R ABU-RUSTUM, Diego ODETTO, Jaroslav KLAT, dos Reis RICARDO, Ignacio ZAPARDIEL, Di Martino GIAMPAOLO, Jiri PRESL, Rene LAKY, Aldo LOPEZ, Vít WEINBERGER, Andreas OBERMAIR, Rene PAREJA, Renata PONCOVA, Constantijne MOM, Nicolo BIZZARRI, Martina BORCINOVA, Koray ASLAN, Rosa Angelica Salcedo HERNANDEZ, Guus FONS, Klára BENEŠOVÁ, Lukas DOSTALEK a Ali AYHAN. Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study. \textit{Gynecologic oncology}. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2023, roč.~170, March 2023, s.~195-202. ISSN~0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2023.01.014.

Podrobný výpis o publikaci